Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 2/2015

01.06.2015 | review

New targets in breast cancer

verfasst von: MD Ami Jhaveri, MD, DPhil Lajos Pusztai

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2015

Einloggen, um Zugang zu erhalten
share
TEILEN

Abstract

In the past few years, the therapeutic strategies for breast cancer have broadened substantially beyond endocrine therapy, chemotherapy, and human epidermal growth factor receptor 2-targeted agents to include several new drugs with unique mechanism of actions including antibody–drug conjugates, inhibitors of the phosphoinositide 3-kinase/Akt/mammalian target of rapamycin pathway, cyclin-dependent kinases 4/6, histone deacetylases and the poly ADP ribose polymerase as well as immune checkpoint modulators. Novel clinical trial designs are also being implemented in the clinic to assess the therapeutic potential of targeting rare molecular abnormalities observed in breast cancers (fibroblast growth factor receptor amplification, inactivating mutations in BRCA, activating mutations in HER2, epidermal growth factor receptor, c-Kit, Akt, etc.).
Literatur
1.
Zurück zum Zitat Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010;12(5):R68. PubMedCentralPubMedCrossRef Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010;12(5):R68. PubMedCentralPubMedCrossRef
2.
Zurück zum Zitat Abd El-Rehim DM, Pinder SE, Paish CE, Bell J, Blamey RW, Robertson JF, et al. Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol. 2004;203(2):661–71. PubMedCrossRef Abd El-Rehim DM, Pinder SE, Paish CE, Bell J, Blamey RW, Robertson JF, et al. Expression of luminal and basal cytokeratins in human breast carcinoma. J Pathol. 2004;203(2):661–71. PubMedCrossRef
3.
Zurück zum Zitat Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003;100(14):8418–23. PubMedCentralPubMedCrossRef Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003;100(14):8418–23. PubMedCentralPubMedCrossRef
4.
Zurück zum Zitat Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61–70. CrossRef Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61–70. CrossRef
5.
Zurück zum Zitat Parker JS, Mullins M, Cheang MCU, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27(8):1160–7. PubMedCentralPubMedCrossRef Parker JS, Mullins M, Cheang MCU, Leung S, Voduc D, Vickery T, et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol. 2009;27(8):1160–7. PubMedCentralPubMedCrossRef
6.
Zurück zum Zitat Baselga J, Campone M, Piccart M, Burris HA, III, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366(6):520–9. PubMedCrossRef Baselga J, Campone M, Piccart M, Burris HA, III, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366(6):520–9. PubMedCrossRef
7.
Zurück zum Zitat Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Ro J, et al. O1-030PHASE II STUDY OF PALBOCICLIB (PD-0332991) + LETROZOLE VS LETROZOLE ALONE IN FIRST-LINE ER + /HER2- ADVANCED BREAST CANCER. Ann Oncol. 2013;24(Suppl 9):ix32–3. CrossRef Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Ro J, et al. O1-030PHASE II STUDY OF PALBOCICLIB (PD-0332991) + LETROZOLE VS LETROZOLE ALONE IN FIRST-LINE ER + /HER2- ADVANCED BREAST CANCER. Ann Oncol. 2013;24(Suppl 9):ix32–3. CrossRef
8.
Zurück zum Zitat Yardley DA, Ismail-Khan RR, Melichar B, Lichinitser M, Munster PN, Klein PM, et al. Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. J Clin Oncol. 2013;31(17):2128–35. PubMedCrossRef Yardley DA, Ismail-Khan RR, Melichar B, Lichinitser M, Munster PN, Klein PM, et al. Randomized phase II, double-blind, placebo-controlled study of exemestane with or without entinostat in postmenopausal women with locally recurrent or metastatic estrogen receptor-positive breast cancer progressing on treatment with a nonsteroidal aromatase inhibitor. J Clin Oncol. 2013;31(17):2128–35. PubMedCrossRef
9.
Zurück zum Zitat Munster PN, Thurn KT, Thomas S, Raha P, Lacevic M, Miller A, et al. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer. 2011;104(12):1828–35. PubMedCentralPubMedCrossRef Munster PN, Thurn KT, Thomas S, Raha P, Lacevic M, Miller A, et al. A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer. 2011;104(12):1828–35. PubMedCentralPubMedCrossRef
10.
Zurück zum Zitat Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014;32:2959–67. PubMedCrossRef Adams S, Gray RJ, Demaria S, Goldstein L, Perez EA, Shulman LN, et al. Prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancers from two phase III randomized adjuvant breast cancer trials: ECOG 2197 and ECOG 1199. J Clin Oncol. 2014;32:2959–67. PubMedCrossRef
11.
Zurück zum Zitat Miller TW, Rexer BN, Garrett JT, Arteaga CL. Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res. 2011;13(6):224. PubMedCentralPubMedCrossRef Miller TW, Rexer BN, Garrett JT, Arteaga CL. Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer Res. 2011;13(6):224. PubMedCentralPubMedCrossRef
12.
Zurück zum Zitat Miller TW, Balko JM, Arteaga CL. Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J Clin Oncol. 2011;29(33):4452–61. PubMedCentralPubMedCrossRef Miller TW, Balko JM, Arteaga CL. Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer. J Clin Oncol. 2011;29(33):4452–61. PubMedCentralPubMedCrossRef
13.
Zurück zum Zitat Yardley DA, Noguchi S, Pritchard KI, Burris HA, III, Baselga J, Gnant M, et al. Everolimus plus exemestane in postmenopausal patients with HR( + ) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther. 2013;30(10):870–84. PubMedCentralPubMedCrossRef Yardley DA, Noguchi S, Pritchard KI, Burris HA, III, Baselga J, Gnant M, et al. Everolimus plus exemestane in postmenopausal patients with HR( + ) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther. 2013;30(10):870–84. PubMedCentralPubMedCrossRef
14.
Zurück zum Zitat Bendell JC, Rodon J, Burris HA, de Jonge M, Verweij J, Birle D, et al. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2012;30(3):282–90. PubMedCrossRef Bendell JC, Rodon J, Burris HA, de Jonge M, Verweij J, Birle D, et al. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2012;30(3):282–90. PubMedCrossRef
15.
Zurück zum Zitat Iwata H, et al. Ph III randomized studies of the oral pan-PI3K inhibitor buparlisib (BKM120) with fulvestrant in postmenopausal women with HR/HER2- locally advanced or metastatic breast cancer (BC) after aromatase inhibitor (AI; BELLE-2) or AI and mTOR inhibitor (BELLE-3) treatment. ASCO Meeting Abstracts. 2013;31:TPS650. Iwata H, et al. Ph III randomized studies of the oral pan-PI3K inhibitor buparlisib (BKM120) with fulvestrant in postmenopausal women with HR/HER2- locally advanced or metastatic breast cancer (BC) after aromatase inhibitor (AI; BELLE-2) or AI and mTOR inhibitor (BELLE-3) treatment. ASCO Meeting Abstracts. 2013;31:TPS650.
16.
Zurück zum Zitat Morrow PK, Wulf GM, Ensor J, Booser DJ, Moore JA, Flores PR, et al. Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. J Clin Oncol. 2011;29(23):3126–32. PubMedCentralPubMedCrossRef Morrow PK, Wulf GM, Ensor J, Booser DJ, Moore JA, Flores PR, et al. Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. J Clin Oncol. 2011;29(23):3126–32. PubMedCentralPubMedCrossRef
17.
Zurück zum Zitat O’Regan R, Ozguroglu M, Andre F, et al. Phase III, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and vinorelbine in trastuzumab-resistant, advanced breast cancer (BOLERO-3). J Clin Oncol. 2013;31(Suppl; abstr 505). O’Regan R, Ozguroglu M, Andre F, et al. Phase III, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and vinorelbine in trastuzumab-resistant, advanced breast cancer (BOLERO-3). J Clin Oncol. 2013;31(Suppl; abstr 505).
18.
Zurück zum Zitat Saura C, Bendell J, Jerusalem G, Su S, Ru Q, De Buck S, et al. Phase Ib study of buparlisib plus trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on trastuzumab-based therapy. Clin Cancer Res. 2014;20(7):1935–45. PubMedCrossRef Saura C, Bendell J, Jerusalem G, Su S, Ru Q, De Buck S, et al. Phase Ib study of buparlisib plus trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on trastuzumab-based therapy. Clin Cancer Res. 2014;20(7):1935–45. PubMedCrossRef
19.
Zurück zum Zitat Goncalves A IN, Campone M, et al. PIKHER2: a phase Ib/II study evaluating safety and efficacy of oral BKM120 in combination with lapatinib in HER2-positive, PI3K-activated, trastuzumab-resistant advanced breast cancer. J Clin Oncol. 2013;31(Suppl; abstr TPS663). Goncalves A IN, Campone M, et al. PIKHER2: a phase Ib/II study evaluating safety and efficacy of oral BKM120 in combination with lapatinib in HER2-positive, PI3K-activated, trastuzumab-resistant advanced breast cancer. J Clin Oncol. 2013;31(Suppl; abstr TPS663).
20.
Zurück zum Zitat Rugo HS, Olopade O, DeMichele A, et al. Veliparib/carboplatin plus standard neoadjuvant chemotherapy for high-risk breast cancer. First efficacy results from the I-SPY 2 trial. Program and abstracts of the 2013 San Antonio Breast Cancer Symposium; December 10–14, 2013; San Antonio, Abstract S5-02; 2013. Rugo HS, Olopade O, DeMichele A, et al. Veliparib/carboplatin plus standard neoadjuvant chemotherapy for high-risk breast cancer. First efficacy results from the I-SPY 2 trial. Program and abstracts of the 2013 San Antonio Breast Cancer Symposium; December 10–14, 2013; San Antonio, Abstract S5-02; 2013.
21.
Zurück zum Zitat Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol. 2008;26(22):3785–90. PubMedCrossRef Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol. 2008;26(22):3785–90. PubMedCrossRef
22.
Zurück zum Zitat Mina LA, Wainberg ZA, Ramanathan RK, et al. Update on first-inhuman trial of novel PARP inhibitor BMN 673 in patients with solid tumors. Poster presented at 2013 San Antonio Breast Cancer Symposium, December 10–14, 2013, San Antonio, P2-09–02. Mina LA, Wainberg ZA, Ramanathan RK, et al. Update on first-inhuman trial of novel PARP inhibitor BMN 673 in patients with solid tumors. Poster presented at 2013 San Antonio Breast Cancer Symposium, December 10–14, 2013, San Antonio, P2-09–02.
23.
Zurück zum Zitat Gucalp A, Tolaney S, Isakoff SJ, Ingle JN, Liu MC, Carey LA, et al. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer. Clin Cancer Res. 2013;19(19):5505–12. PubMedCentralPubMedCrossRef Gucalp A, Tolaney S, Isakoff SJ, Ingle JN, Liu MC, Carey LA, et al. Phase II trial of bicalutamide in patients with androgen receptor-positive, estrogen receptor-negative metastatic breast cancer. Clin Cancer Res. 2013;19(19):5505–12. PubMedCentralPubMedCrossRef
24.
Zurück zum Zitat Traina TA. 10P A phase 1 open-label study evaluating the safety, tolerability, and pharmacokinetics of enzalutamide alone or combined with an aromatase inhibitor in women with advanced breast cancer. Ann Oncol. 2014;25(Suppl_1):i4. doi:10.1093/annonc/mdu064. CrossRef Traina TA. 10P A phase 1 open-label study evaluating the safety, tolerability, and pharmacokinetics of enzalutamide alone or combined with an aromatase inhibitor in women with advanced breast cancer. Ann Oncol. 2014;25(Suppl_1):i4. doi:10.1093/annonc/mdu064. CrossRef
25.
Zurück zum Zitat Capper CP, Johnson MD, Larios JM, Rae JM. Abstract 5568: CYP17A1 and abiraterone: implications for breast cancer endocrine therapy. Cancer Res. 2014;74(Suppl. 19):5568. CrossRef Capper CP, Johnson MD, Larios JM, Rae JM. Abstract 5568: CYP17A1 and abiraterone: implications for breast cancer endocrine therapy. Cancer Res. 2014;74(Suppl. 19):5568. CrossRef
26.
Zurück zum Zitat ClinicalTrials.gov [Internet] Bethesda (MD): National Library of Medicine (US). 2014 Dec 15. Identifier NCT01381874, randomized phase 2 study of abiraterone acetate (AA) with or without exemestane (E) in postmenopausal patients (pts) with estrogen receptor-positive (ER + ) metastatic breast cancer (MBC). 2014. https://​clinicaltrials.​gov/​ct2/​show/​NCT01381874. ClinicalTrials.gov [Internet] Bethesda (MD): National Library of Medicine (US). 2014 Dec 15. Identifier NCT01381874, randomized phase 2 study of abiraterone acetate (AA) with or without exemestane (E) in postmenopausal patients (pts) with estrogen receptor-positive (ER + ) metastatic breast cancer (MBC). 2014. https://​clinicaltrials.​gov/​ct2/​show/​NCT01381874.
27.
Zurück zum Zitat Dalton J, Narayanan R, Steiner M. Abstract P5-09-21: selective androgen receptor modulators (SARMs): enobosarm as targeted therapy for the treatment of androgen receptor-positive breast cancer. Cancer Res. 2013;73(Suppl. 24):P5-09–21. Dalton J, Narayanan R, Steiner M. Abstract P5-09-21: selective androgen receptor modulators (SARMs): enobosarm as targeted therapy for the treatment of androgen receptor-positive breast cancer. Cancer Res. 2013;73(Suppl. 24):P5-09–21.
28.
Zurück zum Zitat Tate C, Rhodes L, Segar HC, Driver J, Pounder FN, Burow M, et al. Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat. Breast Cancer Res. 2012;14(3):R79. PubMedCentralPubMedCrossRef Tate C, Rhodes L, Segar HC, Driver J, Pounder FN, Burow M, et al. Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat. Breast Cancer Res. 2012;14(3):R79. PubMedCentralPubMedCrossRef
29.
Zurück zum Zitat Conte P, Campone P, Pronzato D, et al. Phase I trial of panobinostat (LBH589) in combination with trastuzumab in pretreated HER2-positive metastatic breast cancer (mBC): preliminary safety and tolerability results. J Clin Oncol. 2009;27:15s(Suppl; abstr 1081). CrossRef Conte P, Campone P, Pronzato D, et al. Phase I trial of panobinostat (LBH589) in combination with trastuzumab in pretreated HER2-positive metastatic breast cancer (mBC): preliminary safety and tolerability results. J Clin Oncol. 2009;27:15s(Suppl; abstr 1081). CrossRef
30.
Zurück zum Zitat Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol. 2013;31(7):860–7. PubMedCrossRef Loi S, Sirtaine N, Piette F, Salgado R, Viale G, Van Eenoo F, et al. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98. J Clin Oncol. 2013;31(7):860–7. PubMedCrossRef
31.
Zurück zum Zitat Zitvogel L, Apetoh L, Ghiringhelli F, Andre F, Tesniere A, Kroemer G. The anticancer immune response: indispensable for therapeutic success? J Clin Invest. 2008;118(6):1991–2001. PubMedCentralPubMedCrossRef Zitvogel L, Apetoh L, Ghiringhelli F, Andre F, Tesniere A, Kroemer G. The anticancer immune response: indispensable for therapeutic success? J Clin Invest. 2008;118(6):1991–2001. PubMedCentralPubMedCrossRef
32.
Zurück zum Zitat Schalper KA, Velcheti V, Carvajal D, Wimberly H, Brown J, Pusztai L, et al. In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. Clin Cancer Res. 2014;20(10):2773–82. PubMedCrossRef Schalper KA, Velcheti V, Carvajal D, Wimberly H, Brown J, Pusztai L, et al. In situ tumor PD-L1 mRNA expression is associated with increased TILs and better outcome in breast carcinomas. Clin Cancer Res. 2014;20(10):2773–82. PubMedCrossRef
33.
Zurück zum Zitat Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res. 2014;2(4):361–70. PubMedCentralPubMedCrossRef Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res. 2014;2(4):361–70. PubMedCentralPubMedCrossRef
34.
Zurück zum Zitat Ghebeh H, Barhoush E, Tulbah A, Elkum N, Al-Tweigeri T, Dermime S. FOXP3 + Tregs and B7-H1 + /PD-1 + T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: implication for immunotherapy. BMC Cancer. 2008;8:57. PubMedCentralPubMedCrossRef Ghebeh H, Barhoush E, Tulbah A, Elkum N, Al-Tweigeri T, Dermime S. FOXP3 + Tregs and B7-H1 + /PD-1 + T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: implication for immunotherapy. BMC Cancer. 2008;8:57. PubMedCentralPubMedCrossRef
35.
Zurück zum Zitat Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455–65. PubMedCentralPubMedCrossRef Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455–65. PubMedCentralPubMedCrossRef
36.
Zurück zum Zitat Herbst RS, Gordon MS, Fine GD, Sosman JA, Soria JC, Hamid O, et al. A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors. J Clin Oncol. 2013;31(Suppl; abstr 3000). Herbst RS, Gordon MS, Fine GD, Sosman JA, Soria JC, Hamid O, et al. A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors. J Clin Oncol. 2013;31(Suppl; abstr 3000).
37.
Zurück zum Zitat Adams CW, Allison DE, Flagella K, Presta L, Clarke J, Dybdal N, et al. Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol Immunother. 2006;55(6):717–27. PubMedCrossRef Adams CW, Allison DE, Flagella K, Presta L, Clarke J, Dybdal N, et al. Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol Immunother. 2006;55(6):717–27. PubMedCrossRef
38.
Zurück zum Zitat Baselga J, Cortés J, Kim S-B, Im S-A, Hegg R, Im Y-H, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366(2):109–19. PubMedCrossRef Baselga J, Cortés J, Kim S-B, Im S-A, Hegg R, Im Y-H, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366(2):109–19. PubMedCrossRef
39.
Zurück zum Zitat Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(1):25–32. PubMedCrossRef Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(1):25–32. PubMedCrossRef
40.
Zurück zum Zitat Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008;68(22):9280–90. PubMedCrossRef Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008;68(22):9280–90. PubMedCrossRef
41.
Zurück zum Zitat Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783–91. PubMedCrossRef Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783–91. PubMedCrossRef
42.
43.
Zurück zum Zitat Park JW, Liu MC, Yee D, et al. Neratinib plus standard neoadjuvant therapy for high-risk breast cancer: efficacy results from the I-SPY 2 trial. 2014 AACR Annual Meeting. Abstract CT227. Presented April 7, 2014. Park JW, Liu MC, Yee D, et al. Neratinib plus standard neoadjuvant therapy for high-risk breast cancer: efficacy results from the I-SPY 2 trial. 2014 AACR Annual Meeting. Abstract CT227. Presented April 7, 2014.
44.
Zurück zum Zitat Sussman D, Smith LM, Anderson ME, Duniho S, Hunter JH, Kostner H, et al. SGN-LIV1A: A Novel Antibody-Drug Conjugate Targeting LIV-1 for the Treatment of Metastatic Breast Cancer. Mol Cancer Ther. 2014;13:2991–3000. PubMedCrossRef Sussman D, Smith LM, Anderson ME, Duniho S, Hunter JH, Kostner H, et al. SGN-LIV1A: A Novel Antibody-Drug Conjugate Targeting LIV-1 for the Treatment of Metastatic Breast Cancer. Mol Cancer Ther. 2014;13:2991–3000. PubMedCrossRef
45.
Zurück zum Zitat Yardley DA WR, Melisko M, et al. A randomized phase 2 study of the antibody-drug conjugate CDX-011 in advanced GPNMB-overexpressing breast cancer: The EMERGE study. Cancer Res. 2012;72(24s3):P6-10–01. Yardley DA WR, Melisko M, et al. A randomized phase 2 study of the antibody-drug conjugate CDX-011 in advanced GPNMB-overexpressing breast cancer: The EMERGE study. Cancer Res. 2012;72(24s3):P6-10–01.
46.
Zurück zum Zitat Vasan N, Yelensky R, Wang K, Moulder S, Dzimitrowicz H, Avritscher R, et al. A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for clinical practice. Oncologist. 2014;19(5):453–8. PubMedCentralPubMedCrossRef Vasan N, Yelensky R, Wang K, Moulder S, Dzimitrowicz H, Avritscher R, et al. A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for clinical practice. Oncologist. 2014;19(5):453–8. PubMedCentralPubMedCrossRef
47.
Zurück zum Zitat Willyard C. ‘Basket studies’ will hold intricate data for cancer drug approvals. Nat Med. 2013;19(6):655. PubMedCrossRef Willyard C. ‘Basket studies’ will hold intricate data for cancer drug approvals. Nat Med. 2013;19(6):655. PubMedCrossRef
Metadaten
Titel
New targets in breast cancer
verfasst von
MD Ami Jhaveri
MD, DPhil Lajos Pusztai
Publikationsdatum
01.06.2015
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 2/2015
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-015-0197-5